Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation

Journal of Pathology

Volumn 200, Issue 2, 2003, Pages 214-221

  Dürkop, Horst ^a   Hirsch, Burkhard ^a   Hahn, Corinna ^a   Foss, Hans Dieter ^a   Stein, Harald ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

A20; Anaplastic large cell lymphoma; CD30; Hodgkin lymphoma; TRAF1

Indexed keywords

CD30 ANTIGEN; CELL PROTEIN; PROTEIN A20; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BLAST CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; IMMUNOSTIMULATION; IN VIVO STUDY; LARGE CELL LYMPHOMA; LYMPHOID CELL; MAJOR CLINICAL STUDY; NODULAR LYMPHOMATOSIS; NONHODGKIN LYMPHOMA; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; REED STERNBERG CELL; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; TONSIL CELL; TUMOR CELL;

EID: 0041998173     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1351     Document Type: Article

References (58)

1. Küppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994; 91: 10 962-10 966.
2. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of single clone originating from germinal centre B cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95: 1443-1450.
3. Lam KP, Kühn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997; 90: 1073-1083.
4. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848-858.
5. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65-67.
6. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421-427.
7. Amakawa R, Hakem A, Kundig TM, et al. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 1996; 84: 551-562.
8. Telford WG, Nam SY, Podack ER, Miller RA. CD30-regulated apoptosis in murine CD8 T cells after cessation of TCR signals. Cell Immunol 1997; 182: 125-136.
9. Kurts C, Carbone FR, Krummel MF, Koch KM, Miller JF, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature 1999; 398: 341-344.
10. Lee SY, Kandala G, Liou ML, Liou HC, Choi Y. CD30/TNF receptor-associated factor interaction: NF-κB activation and binding specificity. Proc Natl Acad Sci USA 1996; 93: 9699-9703.
11. Lee SY, Park CG, Choi Y. T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors. J Exp Med 1996; 183: 669-674.
12. Gedrich RW, Gilfillan MC, Duckett CS, Van Dongen JL, Thompson CB. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J Biol Chem 1996; 271: 12 852-12 858.
13. Boucher LM, Marengere LE, Lu Y, Thukral S, Mak TW. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem Biophys Res Commun 1997; 233: 592-600.
14. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NF-κB activation. J Biol Chem 1997; 272: 2042-2045.
15. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95, and IL-1. Nature 1997; 385: 540-544.
16. Pomerantz JL, Baltimore D. NF-κB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 1999; 18: 6694-6704.
17. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity 1997; 7: 703-713.
18. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 in yeast and causes cell death. Cell 1995; 81: 513-523.
19. Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J 1996; 15: 6189-6196.
20. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD-homologous ICE/CED3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-827.
21. Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995; 83: 1243-1252.
22. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349-1360.
23. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and hodgkin disease cells. Blood 2000; 96: 4307-4312.
24. Dürkop H, Foss HD, Demel G, Klotzbach H, Hahn C, Stein H. TRAF1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and EBV-transformed lymphoid cells. Blood 1999; 93: 617-623.
25. Speiser DE, Lee SY, Wong B, et al. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. J Exp Med 1997; 185: 1777-1783.
26. Fries KL, Miller WE, Raab-Traub N. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996; 70: 8653-8659.
27. Opipari AW, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem 1992; 267: 12 424-12 427.
28. Tewari M, Wolf FW, Seldin MF, O'Shea KS, Dixit VM, Turka LA. Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J Immunol 1995; 154: 1699-1706.
29. Ferran C, Stroka DM, Badrichani AZ, et al. A20 inhibits NF-κB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood 1998; 91: 2249-2258.
30. Jaffe ES, Harris NL, Stein H, Vardiman JM. World Health Organization Classification of Tumours, Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001.
31. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
32. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor β-chain gene. Blood 1988; 72: 234-240.
33. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-399.
34. Grell M, Zimmermann G, Gottfried E, et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J 1999; 18: 3034-3043.
35. + T-helper cells. Am J Pathol 1992; 140: 15-22.
36. Herbst H, Steinbrecher E, Niedobitek G, et al. Distribution and phenotype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood 1992; 80: 484-491.
37. Cordell J, Falini B, Erber ON, et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-229.
38. Mason DY, Stein H, Naiem M, Abdulaziz Z. Immunohistological analysis of human lymphoid tissue by double immunoenzymatic labelling. J Cancer Res Clin Oncol 1981; 101: 13-22.
39. Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J. Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res 1986; 10: 487-492.
40. Kamesaki H, Fukuhara S, Tatsumi E, et al. Cytochemical, immunological, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 1986; 68: 285-292.
41. Wasik MA, Sioutos N, Tuttle M, Butmarc JR, Kaplan WD, Kadin ME. Constitutive secretion of soluble IL-2 receptor by human T-cell lymphoma xenografted into SCID mice: correlation of tumor volume with concentration of tumor-derived soluble IL-2R in body fluids of the host mice. Am J Pathol 1994; 144: 1089-1097.
42. Diehl V, Pfreundschuh M, Fonatsch C, et al. Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications. Cancer Surv 1985; 4: 399-419.
43. Ausubel FM, Brent R, Kingston. RE, et al. Current Protocols in Molecular Biology. Wiley Interscience: New York, 2002.
44. Arcari P, Martinelli R, Salvatore F. The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res 1984; 12: 9179-9189.
45. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocytes apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271-279.
46. Muta H, Boise LH, Fang L, Podack ER. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J Immunol 2000; 165: 5105-5111.
47. Sarma V, Lin Z, Clark L, et al. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem 1995; 21: 12 343-12 346.
48. Schwenzer R, Siemienski K, Liptay S, et al. The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem 1999; 274: 19 368-19 374.
49. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 1992; 267: 24 157-24 160.
50. Wood KM, Roff M, Hay RT. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB. Oncogene 1998; 16: 2131-2139.
51. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-2969.
52. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-κB/Rel activation in Hodkin/Reed-Sternberg cells. Oncogene 1999; 18: 943-953.
53. Emmerich F, Meiser M, Hummel M, et al. Overexpression of IκBα without inhibition of NF-κB activity and mutations in the IκBα gene in Reed-Sternberg cells. Blood 1999; 94: 3129-3134.
54. Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191: 395-402.
55. Horie R, Watanabe T, Morishita Y, et al. Ligand-independent signaling by overexpressed CD30 drives NF-kB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002; 21: 2493-2503.
56. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000; 156: 1723-1731.
57. Kadin ME. Regulation of CD30 antigen expression and its potential significance for human disease. Am J Pathol 2000; 156: 1479-1484.
58. + cell lines. Biochim Biophys Acta 2001; 1519: 185-191.